Poxel is a research integrated pharmaceutical company that develops products for metabolic diseases.
Poxel is a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time.They believe that targeting cellular energy regulation pathways for the treatment of metabolic diseases, including type 2 diabetes is of critical importance as disbalances are at the root of those diseases. All three of their clinical stage pipeline programs address significant targets in the energy metabolism pathways. Imeglimin, their lead program, targets mitochondrial dysfunction, mitochondria being the power station of the cell, PXL770 activates the adenosine monophosphate-activated protein kinase (AMPK), an important energy sensor, and PXL065 (DRX-065) inhibits the mitochondrial pyruvate carrier (MPC).
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 9, 2014 | Series B | $13.50M | 1 | — | — | Detail |
Dec 18, 2012 | Series B | €13M | 1 | — | — | Detail |
Jul 8, 2010 | Series A | $21M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Kreos Capital | — | Series B |
InnoBio Fund | — | Series B |